Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) Return on Capital Employed (2024 - 2026)

Kura Oncology has reported Return on Capital Employed over the past 3 years, most recently at 3.45% for Q1 2026.

  • Quarterly Return on Capital Employed rose 2463.0% to 3.45% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 3.45% through Mar 2026, up 2463.0% year-over-year, with the annual reading at 48.02% for FY2025, 1128.0% down from the prior year.
  • Return on Capital Employed was 3.45% for Q1 2026 at Kura Oncology, down from 1.1% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 1.1% in Q4 2025 and troughed at 40.57% in Q3 2025.
  • The 3-year median for Return on Capital Employed is 29.79% (2024), against an average of 22.98%.
  • Year-over-year, Return on Capital Employed skyrocketed 3040bps in 2025 and then surged 2463bps in 2026.
  • A 3-year view of Return on Capital Employed shows it stood at 31.5% in 2024, then skyrocketed by 96bps to 1.1% in 2025, then tumbled by -212bps to 3.45% in 2026.
  • Per Business Quant, the three most recent readings for KURA's Return on Capital Employed are 3.45% (Q1 2026), 1.1% (Q4 2025), and 40.57% (Q3 2025).